This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...
Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...
Queen Mary University of London has launched a new spinout company, Elcella, founded by Dr Madusha Peiris and Dr Rubina Aktar ...